95523-13-0

Usage

Uses

Used in Pharmaceutical Industry:
N6-(P-aminobenzyl)adenosine is used as a therapeutic agent for the treatment of various medical conditions, such as cardiovascular diseases, neurological disorders, and cancer. Its agonistic action on the adenosine A1 receptor helps in modulating the associated signaling pathways, which can contribute to the management and treatment of these conditions.
Used in Research and Drug Development:
N6-(P-aminobenzyl)adenosine is used as a research tool for studying adenosine receptor pharmacology and biochemistry. Its selectivity for the A1 receptor makes it a valuable compound for investigating the role of adenosine receptors in various physiological and pathological processes. This can aid in the development of new drugs targeting these receptors and contribute to a better understanding of their function in the body.
Used in Immunology and Inflammation Research:
N6-(P-aminobenzyl)adenosine is used as a modulator of immune responses and inflammatory processes. Its effects on the adenosine A1 receptor can help in understanding the role of adenosine signaling in immune regulation and inflammation. This can lead to the development of new therapeutic strategies for managing inflammatory and immune-related disorders.

InChI:InChI=1/C17H20N6O4/c18-10-3-1-9(2-4-10)5-19-15-12-16(21-7-20-15)23(8-22-12)17-14(26)13(25)11(6-24)27-17/h1-4,7-8,11,13-14,17,24-26H,5-6,18H2,(H,19,20,21)/t11-,13-,14-,17-/m1/s1

Upstream product

• 40297-54-9 N6-(p-Nirobenzyl)adenosine 
• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 556-18-3 4-aminobenzaldehyde 
• 2004-06-0 6-Chloropurine riboside 
• 140401-57-6 4-(aminomethyl)aniline monohydrochloride 
• 58-63-9 Inosine 
• 5987-73-5 2',3',5'-O-triacetyl-6-chloroinosine 
• 3181-38-2 2',3',5'-tri-O-acetylinosine 
• 3419-18-9 4-aminobenzaldehyde oxime 
• 4403-71-8 (4-aminomethyl)aniline 
• 58-61-7 adenosine 
• 112533-71-8 Acetic acid (2R,3R,4R,5R)-4-acetoxy-5-acetoxymethyl-2-[6-(4-nitro-benzylamino)-purin-9-yl]-tetrahydro-furan-3-yl ester 

Downstream Products

• 98866-49-0 N-[(4-amino-3-iodophenyl)methyl]-Adenosine 
• 56527-35-6 6-N-<4-(acetamido)benzyl>adenosine 

Relevant academic research and scientific papers

APPLICATIONS OF N6-SUBSTITUTED ADENOSINE DERIVATIVE AND N6-SUBSTITUTED ADENINE DERIVATIVE TO CALMING, HYPNOSES, CONVULSION RESISTANCE, EPILEPTIC RESISTANCE, PARKINSON DISEASE RESISTANCE, AND DEMENTIA PREVENTION AND TREATMENT

PROBLEM TO BE SOLVED: To prepare analgesics, hypnotic agents, anticonvulsant agents, antiepileptics, antiparkinson drugs, dementia prophylactics, and health care food. SOLUTION: The present invention relates to an N6-substituted adenosine derivative and an N6-substituted adenine derivative selected from the group consisting of specific compounds. The present invention also relates to a pharmaceutical composition at least comprising a therapeutically effective amount of the compounds and a pharmaceutically acceptable carrier. The invention further relates to the compounds used in preparation of analgesics, hypnotic agents, anticonvulsant agents, antiepileptics, antiparkinson drugs, dementia prophylactics, and health care food. COPYRIGHT: (C)2016,JPO&INPIT

α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5′-Nucleotidase (CD73) Inhibitors

ecto-5′-Nucleotidase (eN, CD73) catalyzes the hydrolysis of extracellular AMP to adenosine. eN inhibitors have potential for use as cancer therapeutics. The eN inhibitor α,β-methylene-ADP (AOPCP, adenosine-5′-O-[(phosphonomethyl)phosphonic acid]) was used as a lead structure, and derivatives modified in various positions were prepared. Products were tested at rat recombinant eN. 6-(Ar)alkylamino substitution led to the largest improvement in potency. N6-Monosubstitution was superior to symmetrical N6,N6-disubstitution. The most potent inhibitors were N6-(4-chlorobenzyl)- (10l, PSB-12441, Ki 7.23 nM), N6-phenylethyl- (10h, PSB-12425, Ki 8.04 nM), and N6-benzyl-adenosine-5′-O-[(phosphonomethyl)phosphonic acid] (10g, PSB-12379, Ki 9.03 nM). Replacement of the 6-NH group in 10g by O (10q, PSB-12431) or S (10r, PSB-12553) yielded equally potent inhibitors (10q, 9.20 nM; 10r, 9.50 nM). Selected compounds investigated at the human enzyme did not show species differences; they displayed high selectivity versus other ecto-nucleotidases and ADP-activated P2Y receptors. Moreover, high metabolic stability was observed. These compounds represent the most potent eN inhibitors described to date.

N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF

The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.

N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF

The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.

Anti-HCV nucleoside derivatives

The present invention comprises novel and known purine and pyrimidine nucleoside derivatives which have been discovered to be active against hepatitis C virus (HCV). The use of these derivatives for the treatment of HCV infection is claimed as are the novel nucleoside derivatives disclosed herein.

Synthesis of substituted-benzyl and sugar-modified analogues of 6-N-(4- nitrobenzyl)adenosine and their interactions with 'ES' nucleoside transport systems

Four classes of 6-X-benzylated purine nucleosides, (i) 6-N-(substituted- benzyl)adenosines, (ii) 6-N-(4-nitrobenzyl)adenine nucleosides with modified sugars, (iii) 6-N(S)-(4-azidobenzyl) derivatives of adenosine, 6-thioinosine, and 6-thioguanosine, and (iv) 6-N-{4-N-[acyl(sulfonyl)amino]benzyl} adenosines, were synthesized and their binding interactions with 'es-NT' (equilibrative, inhibitor-sensitive nucleoside transport) systems were studied. Several tight-binding analogues were found.

125I-labeled 8-phenylxanthine derivatives: antagonist radioligands for adenosine A1 receptors.

A series of 8-phenylxanthine derivatives has been synthesized with oxyacetic acid on the para phenyl position to increase aqueous solubility and minimize nonspecific binding and iodinatable groups on the 1- or 3-position of the xanthine ring. The structur